Why the Cochrane risk of bias tool should include funding source as a standard item.
作者信息
Bero Lisa A
机构信息
Cochrane Collaboration Steering Group.
出版信息
Cochrane Database Syst Rev. 2013 Dec 20;2013(12):ED000075. doi: 10.1002/14651858.ED000075.
Abstract
摘要
相似文献
1
Why the Cochrane risk of bias tool should include funding source as a standard item.为何Cochrane偏倚风险工具应将资金来源列为标准项目。
Cochrane Database Syst Rev. 2013 Dec 20;2013(12):ED000075. doi: 10.1002/14651858.ED000075.
2
Why the Cochrane risk of bias tool should not include funding source as a standard item.为何Cochrane偏倚风险工具不应将资金来源列为标准项目。
Cochrane Database Syst Rev. 2013 Dec 20;2013(12):ED000076. doi: 10.1002/14651858.ED000076.
3
Industry funding and author-industry affiliation in clinical trials in psychiatry.精神病学临床试验中的行业资助与作者-行业关联
Am J Psychiatry. 2006 Jun;163(6):1110-1; author reply 1111. doi: 10.1176/ajp.2006.163.6.1110a.
4
Addressing conflict in strategic literature reviews: disclosure is not enough.应对战略文献综述中的冲突：仅靠披露是不够的。
J Epidemiol Community Health. 2009 Aug;63(8):599-600. doi: 10.1136/jech.2009.089524.
5
Whether industry-supported or otherwise, trust is key to the acceptance of all research.无论研究是否由行业资助，信任都是所有研究被接受的关键。
J Am Dent Assoc. 2010 Feb;141(2):127-8. doi: 10.14219/jada.archive.2010.0117.
6
Industry sponsorship and research outcome.行业赞助与研究成果。
Cochrane Database Syst Rev. 2017 Feb 16;2(2):MR000033. doi: 10.1002/14651858.MR000033.pub3.
7
Industry-sponsored clinical research: a broken system.行业资助的临床研究：一个漏洞百出的体系。
JAMA. 2008 Sep 3;300(9):1069-71. doi: 10.1001/jama.300.9.1069.
8
The relationship between study sponsorship, risks of bias, and research outcomes in atrazine exposure studies conducted in non-human animals: Systematic review and meta-analysis.非人类动物中阿特拉津暴露研究的研究资助、偏倚风险与研究结果之间的关系：系统评价与荟萃分析
Environ Int. 2016 Jul-Aug;92-93:597-604. doi: 10.1016/j.envint.2015.10.011. Epub 2015 Dec 13.
9
Industry sponsorship and research outcome.行业赞助与研究成果。
Cochrane Database Syst Rev. 2012 Dec 12;12:MR000033. doi: 10.1002/14651858.MR000033.pub2.
10
Systematic reviews and meta-analyses on psoriasis: role of funding sources, conflict of interest and bibliometric indices as predictors of methodological quality.系统评价和荟萃分析在银屑病中的作用：资金来源、利益冲突和文献计量指标作为方法学质量预测因素。
Br J Dermatol. 2017 Jun;176(6):1633-1644. doi: 10.1111/bjd.15380. Epub 2017 May 19.
引用本文的文献
1
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.司美格鲁肽作为一种胰高血糖素样肽-1（GLP-1）激动剂：肥胖治疗的一项突破。
Pharmaceuticals (Basel). 2025 Mar 12;18(3):399. doi: 10.3390/ph18030399.
2
The Evolution of Science and Regulation of Dietary Supplements: Past, Present, and Future.膳食补充剂的科学演变与监管：过去、现在与未来。
J Nutr. 2024 Aug;154(8):2335-2345. doi: 10.1016/j.tjnut.2024.06.017. Epub 2024 Jul 4.
3
Adult Organophosphate and Carbamate Insecticide Exposure and Sperm Concentration: A Systematic Review and Meta-Analysis of the Epidemiological Evidence.成人有机磷和氨基甲酸酯类杀虫剂暴露与精子浓度：系统评价和荟萃分析的流行病学证据。
Environ Health Perspect. 2023 Nov;131(11):116001. doi: 10.1289/EHP12678. Epub 2023 Nov 15.
4
Disclosing and Managing Non-Financial Conflicts of Interest in Scientific Publications.科学出版物中利益冲突的披露与管理：非财务利益冲突
Res Ethics. 2023 Apr;19(2):121-138. doi: 10.1177/17470161221148387. Epub 2023 Jan 12.
5
How about the evidence assessment tools used in education and management systematic reviews?用于教育与管理系统评价的证据评估工具情况如何？
Front Med (Lausanne). 2023 May 9;10:1160289. doi: 10.3389/fmed.2023.1160289. eCollection 2023.
6
Pharmacological interventions for people with borderline personality disorder.药物干预治疗边缘型人格障碍患者。
Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD012956. doi: 10.1002/14651858.CD012956.pub2.
7
Should clinical automated perimetry be considered for routine functional assessment of early/intermediate age-related macular degeneration (AMD)? A systematic review of current literature.临床自动化视野计是否应考虑用于早期/中期年龄相关性黄斑变性（AMD）的常规功能评估？对当前文献的系统回顾。
Ophthalmic Physiol Opt. 2022 Jan;42(1):161-177. doi: 10.1111/opo.12919. Epub 2021 Nov 29.
8
COVID-19 and conjunctivitis: a meta-analysis.新型冠状病毒肺炎与结膜炎：一项荟萃分析。
Ther Adv Ophthalmol. 2021 Mar 25;13:25158414211003368. doi: 10.1177/25158414211003368. eCollection 2021 Jan-Dec.
9
Efficacy of Functional Foods, Beverages, and Supplements Claiming to Alleviate Air Travel Symptoms: Systematic Review and Meta-Analysis.声称可缓解航空旅行症状的功能性食品、饮料及补充剂的功效：系统评价与荟萃分析
Nutrients. 2021 Mar 16;13(3):961. doi: 10.3390/nu13030961.
10
Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study.Cochrane及非Cochrane系统评价中药物试验资金来源及作者利益冲突的报告：一项横断面研究
BMJ Open. 2020 May 11;10(5):e035633. doi: 10.1136/bmjopen-2019-035633.
本文引用的文献
1
The cycle of bias in health research: a framework and toolbox for critical appraisal training.健康研究中的偏见循环：批判性评价培训的框架和工具包。
Account Res. 2013;20(2):127-41. doi: 10.1080/08989621.2013.768931.
2
Industry sponsorship and research outcome.行业赞助与研究成果。
Cochrane Database Syst Rev. 2012 Dec 12;12:MR000033. doi: 10.1002/14651858.MR000033.pub2.
3
Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study.报告 Cochrane 综述中药物试验的利益冲突：横断面研究。
BMJ. 2012 Aug 16;345:e5155. doi: 10.1136/bmj.e5155.
4
Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses.药物试验荟萃分析中报告偏倚的影响：荟萃分析再分析。
BMJ. 2012 Jan 3;344:d7202. doi: 10.1136/bmj.d7202.
5
Outcome reporting in industry-sponsored trials of gabapentin for off-label use.加巴喷丁用于非标签用途的行业资助试验中的结果报告。
N Engl J Med. 2009 Nov 12;361(20):1963-71. doi: 10.1056/NEJMsa0906126.
6
Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others.已发表的药物与药物对比试验结果的相关因素：为何某些他汀类药物似乎比其他药物更有效。
PLoS Med. 2007 Jun;4(6):e184. doi: 10.1371/journal.pmed.0040184.
7
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?随机药物试验中资金与结论的关联：是治疗效果还是不良事件的反映？
JAMA. 2003 Aug 20;290(7):921-8. doi: 10.1001/jama.290.7.921.
8
Design and reporting modifications in industry-sponsored comparative psychopharmacology trials.行业资助的比较精神药理学试验中的设计与报告变更
J Nerv Ment Dis. 2002 Sep;190(9):583-92. doi: 10.1097/00005053-200209000-00002.
9
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?选择性环氧化酶-2抑制剂是否优于传统非甾体抗炎药？
BMJ. 2002 Jun 1;324(7349):1287-8. doi: 10.1136/bmj.324.7349.1287.
Zotero 插件